| Literature DB >> 25374935 |
Abstract
Arsenic contamination of groundwater in different parts of the world is an outcome of natural and/or anthropogenic sources, leading to adverse effects on human health and ecosystem. Millions of people from different countries are heavily dependent on groundwater containing elevated level of As for drinking purposes. As contamination of groundwater, poses a serious risk to human health. Excessive and prolonged exposure of inorganic As with drinking water is causing arsenicosis, a deteriorating and disabling disease characterized by skin lesions and pigmentation of the skin, patches on palm of the hands and soles of the feet. Arsenic poisoning culminates into potentially fatal diseases like skin and internal cancers. This paper reviews sources, speciation, and mobility of As and global overview of groundwater As contamination. The paper also critically reviews the As led human health risks, its uptake, metabolism, and toxicity mechanisms. The paper provides an overview of the state-of-the-art knowledge on the alternative As free drinking water and various technologies (oxidation, coagulation flocculation, adsorption, and microbial) for mitigation of the problem of As contamination of groundwater.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25374935 PMCID: PMC4211162 DOI: 10.1155/2014/304524
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Status of As contamination in natural groundwater in various countries.
| Serial number | Country | Region | Groundwater As level (ppb) | Permissible | References |
|---|---|---|---|---|---|
| 1 | Afghanistan | Ghazni | 10–500 | 10 (WHO) | [ |
| 2 | Australia | Victoria (around the gold-mining regions) | 1–12 (Groundwater); | — | [ |
| 3 | Bangladesh | Noakhali | <1–4730 | 50 (WHO) | [ |
| 4 | Brazil | Minas Gerais | 0.4–350 | 10 (WHO) | [ |
| 5 | Cambodia | Prey Veng and Kandal-Mekong delta | Up to 900 | 10 (WHO) | [ |
| 6 | Canada | Nova Scotia | 1.5–738.8 | 10 (WHO) | [ |
| 7 | China | — | 50–4440 | 50 (WHO) | [ |
| 8 | Finland | Southwest Finland | 17–980 | 10 (WHO) | [ |
| 9 | Greece | Fairbanks | Up to 10,000 | 10 (WHO) | [ |
| 10 | India | West Bengal | 10–3200 | 50 (WHO) | [ |
| 11 | Japan | Fukuoka Prefecture | 1–293 | 10 (WHO) | [ |
| 12 | Mexico | Lagunera | 8–620 | 25 | [ |
| 13 | Nepal | Rupandehi | Up to 2620 | 50 | [ |
| 14 | Pakistan | Muzaffargarh | Up to 906 | 50 | [ |
| 15 | Taiwan | — | 10–1820 | 10 (WHO) | [ |
| 16 | Thailand | Ron Phibun | 1–>5000 | 10 (WHO) | [ |
| 17 | USA | Tulare Lake | Up to 2600 | 10 (USEPA) | [ |
| 18 | Vietnam | Red River Delta | <1–3050 | 10 (WHO) | [ |
Figure 1Pathways of arsenic metabolism in cells: (a) arsenic methylation in Scopulariopsis brevicaulis [54], (b) nonenzymatic As methylation in rat liver [55], (c) arsenic metabolic pathway in rat liver [56], and (d) metabolic pathway in rat liver [58], where SAM: S-adenosylmethionine; SAH: S-adenosylhomocysteine; CH3 +: methyl group; GSH: glutathione; (CH3)(OH)2AsO−: monomethylarsonous acid; (CH3)2(OH)AsO−: dimethylarsinic acid; (CH3)3As: trimethyl arsine oxide; As (GS)3: arsenic triglutathione; MMA: monomethylarsonic acid; DMA: dimethylarsinic acid; MAsIII (GS)2: monomethylarsonic diglutathione; DMAsIII (GS): dimethylarsinic glutathione; DMAsIII: trivalent monomethylarsonous acid; DMAsV: pentavalent dimethylarsinic acid; MMAV: pentavalent monomethylarsonic acid [224].
Figure 2Arsenic toxicity in humans and rats [224].